Cholesterol Treatment Trialists C, Fulcher J, O’Connell R, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–405.

Article  CAS  Google Scholar 

Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–90.

Article  CAS  Google Scholar 

Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685–96.

CAS  PubMed  Article  Google Scholar 

Vallejo-Vaz AJ, Robertson M, Catapano AL, et al. Low-density lipoprotein cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein cholesterol levels of 190 mg/dL or above: analyses from the WOSCOPS (West of Scotland Coronary Prevention Study) 5-year randomized trial and 20-year observational follow-up. Circulation. 2017;136(20):1878–91.

CAS  PubMed  Article  Google Scholar 

Cholesterol Treatment Trialists C. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407–15.

Article  Google Scholar 

Boersma E, Kardys I. The legacy of HOPE-3. Eur Heart J. 2021;42(31):3008–10.

PubMed  Article  Google Scholar 

Penson PE, Bruckert E, Marais D, et al. Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). J Cachexia Sarcopenia Muscle. 2022;13(3):1596–622. https://doi.org/10.1002/jcsm.12960.

Article  PubMed  PubMed Central  Google Scholar 

Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1–full report. J Clin Lipidol. 2015;9(2):129–69.

PubMed  Article  Google Scholar 

Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012–22.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Mancini GBJ, Baker S, Bergeron J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group Update (2016). Can J Cardiol. 2016;32(7, Supplement):S35–65.

PubMed  Article  Google Scholar 

Sposito AC, FariaNeto JR, Carvalho LS, et al. Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium. Curr Med Res Opin. 2017;33(2):239–51.

CAS  PubMed  Article  Google Scholar 

Rosenson RS, Miller K, Bayliss M, et al. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability. Cardiovasc Drugs Ther. 2017;31(2):179–86.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016;67(20):2395–410.

CAS  PubMed  Article  Google Scholar 

Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–61.

CAS  PubMed  Article  Google Scholar 

Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403–14.

CAS  PubMed  Article  Google Scholar 

Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208–15.

PubMed  Article  Google Scholar 

•• Bytyci I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;ehac015. https://doi.org/10.1093/eurheartj/ehac015. This meta-analysis estimates the prevalence of statin intolerance, employing major stakeholder diagnostic criteria, and identifies risk factors and conditions that are associated with increased the risk of statin-associated muscle symptoms.

Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. J Am Med Assoc. 2002;287(5):622–7.

Article  Google Scholar 

Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315(15):1580–90.

CAS  PubMed  Article  Google Scholar 

Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002;287(5):622–7.

PubMed  Article  Google Scholar 

Banach M, Rizzo M, Toth PP, et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11(1):1–23.

PubMed  PubMed Central  Article  Google Scholar 

Herrett E, Williamson E, Brack K, et al. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ. 2021;372:n135. https://doi.org/10.1136/bmj.n135.

Article  PubMed  PubMed Central  Google Scholar 

Wood FA, Howard JP, Finegold JA, et al. N-of-1 Trial of a statin, placebo, or no treatment to assess side effects. N Engl J Med. 2020;383(22):2182–4.

PubMed  Article  Google Scholar 

Kalra DK. Bridging the racial disparity gap in lipid-lowering therapy. J Am Heart Assoc. 2021;10(1): e019533.

PubMed  Article  Google Scholar 

Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009;54(17):1609–16.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy–a genomewide study. N Engl J Med. 2008;359(8):789–99.

CAS  PubMed  Article  Google Scholar 

Naito R, Miyauchi K, Daida H. Racial differences in the cholesterol-lowering effect of statin. J Atheroscler Thromb. 2017;24(1):19–25.

PubMed  PubMed Central  Article  Google Scholar 

• Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38–81. This scientific statement from the American Heart Association provides a comprehensive overview of statin safety and statin associated adverse events in multiple population groups and in individuals with a variety of chronic disease states.

CAS  PubMed  Article  Google Scholar 

Lee JW, Morris JK, Wald NJ. Grapefruit Juice and Statins. Am J Med. 2016;129(1):26–9.

CAS  PubMed  Article  Google Scholar 

Serban MC, Colantonio LD, Manthripragada AD, et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol. 2017;69(11):1386–95.

CAS  PubMed  Article  Google Scholar 

Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940–8.

CAS  PubMed  Article  Google Scholar 

Nasir K, Bittencourt MS, Blaha MJ, et al. Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology/American Heart Association Cholesterol Management Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2015;66(15):1657–68.

CAS  PubMed  Article  Google Scholar 

Grundy SM, Stone NJ. 2018 American Heart Association/American College of Cardiology/Multisociety guideline on the management of blood cholesterol-secondary prevention. JAMA Cardiol. 2019;4(6):589–91.

PubMed  Article  Google Scholar 

Blaha MJ, Budoff MJ, DeFilippis AP, et al. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. The Lancet. 2011;378(9792):684–92.

CAS  Article  Google Scholar 

Orringer CE, Maki KC. HOPE for rational statin allocation for primary prevention: a coronary artery calcium picture is worth 1000 words. Mayo Clin Proc. 2020;95(8):1740–9.

CAS  PubMed  Article  Google Scholar 

Orringer CE, Blaha MJ, Stone NJ. Coronary artery calcium scoring in patients with statin associated muscle symptoms: prescribing statins for those most likely to benefit. J Clin Lipidol. 2021;15(6):782–8.

PubMed  Article  Google Scholar 

Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158(7):526–34.

PubMed  PubMed Central  Article  Google Scholar 

Juszczyk MA, Seip RL, Thompson PD. Decreasing LDL cholesterol and medication cost with every-other-day statin therapy. Prev Cardiol. 2005;8(4):197–9.

PubMed  Article  Google Scholar 

Gadarla M, Kearns AK, Thompson PD. Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol. 2008;101(12):1747–8.

CAS  PubMed  Article  Google Scholar 

Laufs U, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8(7): e011662.

PubMed  PubMed Central  Article